Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Johnson & Johnson or Sanofi because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Johnson & Johnson and Sanofi compare based on key financial metrics to determine which better meets your investment needs.

About Johnson & Johnson and Sanofi

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Latest Pharmaceuticals and Johnson & Johnson, Sanofi Stock News

As of September 2, 2026, Johnson & Johnson had a $663.2 billion market capitalization, compared to the Pharmaceuticals median of $674.0 million. Johnson & Johnson’s stock is up 34.5% in 2026, up 4.8% in the previous five trading days and up 54.56% in the past year.

Currently, Johnson & Johnson’s price-earnings ratio is 31.9. Johnson & Johnson’s trailing 12-month revenue is $97.9 billion with a 21.5% net profit margin. Year-over-year quarterly sales growth most recently was 6.6%. Analysts expect adjusted earnings to reach $11.162 per share for the current fiscal year. Johnson & Johnson currently has a 1.9% dividend yield.

As of September 2, 2026, Sanofi had a $107.2 billion market cap, putting it in the 97th percentile of all stocks. Sanofi’s stock is down 8.5% in 2026, down 1.1% in the previous five trading days and down 10.31% in the past year.

Currently, Sanofi’s price-earnings ratio is 12.0. Sanofi’s trailing 12-month revenue is $55.9 billion with a 8.1% net profit margin. As of September 2, 2026, Sanofi has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $4.986 per share for the current fiscal year. Sanofi currently has a 5.4% dividend yield.

How We Compare Johnson & Johnson and Sanofi Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Johnson & Johnson and Sanofi’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Johnson & Johnson and Sanofi Growth Grades

Company	Ticker	Growth
Johnson & Johnson	JNJ	B
Sanofi	SNY	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Johnson & Johnson has a Growth Score of 73, which is Strong. Sanofi has a Growth Score of 56, which is Average.

The Growth Grade Winner: Johnson & Johnson

As you can clearly see from the Growth Grade breakdown above, Johnson & Johnson has a more attractive growth grade than Sanofi. For investors who focus solely on how a company is growing relative to other companies in the same industry, Johnson & Johnson could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Johnson & Johnson and Sanofi’s Quality Grades

Company	Ticker	Quality
Johnson & Johnson	JNJ	A
Sanofi	SNY	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Johnson & Johnson has a Quality Score of 91, which is Very Strong. Sanofi has a Quality Score of 65, which is Strong.

The Quality Grade Winner: Johnson & Johnson

As you can clearly see from the Quality Grade breakdown above, Johnson & Johnson has a better overall quality grade than Sanofi. For investors who are looking for companies with higher quality than others in the same industry, Johnson & Johnson could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Johnson & Johnson and Sanofi’s Momentum Grades

Company	Ticker	Momentum
Johnson & Johnson	JNJ	A
Sanofi	SNY	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Johnson & Johnson has a Momentum Score of 81, which is Very Strong. Sanofi has a Momentum Score of 32, which is Weak.

The Momentum Grade Winner: Johnson & Johnson

As you can clearly see from the Momentum Grade breakdown above, Johnson & Johnson is considered to have stronger momentum compared to Sanofi. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Johnson & Johnson could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Johnson & Johnson and Sanofi Grades

In addition to Momentum, Growth and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Johnson & Johnson and Sanofi pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Johnson & Johnson or Sanofi Stock?

Overall, Johnson & Johnson stock has a Growth Score of 73, Momentum Score of 81 and Quality Score of 91.

Sanofi stock has a Growth Score of 56, Momentum Score of 32 and Quality Score of 65.

Comparing Johnson & Johnson and Sanofi’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.